Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence

Completed · Phase 2 · Has a placebo group

Conditions studied: Cocaine Dependence

In brief

The purpose of this study is to examine the effects of the administration of Risperidal-Consta on the brain's reward circuitry using Magnetic resonance Imaging (MRI), behavioral tests and measuring cocaine craving and use among people with active cocaine dependence.

Key facts

Study ID

NCT00385801

Run by

Massachusetts General Hospital

People needed

31

Starts

2005-09-01

Expected to finish

2010-09-01

Last updated by the study team

2017-04-28

Who can join

Age: 18 and older, up to 60. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• current cocaine dependence who use cocaine at least every 2 weeks
• Non-treatment seekers who intend to continue using cocaine
• Male 18-60 years of age
• Potential participants must be literate in the English language, and be able to understand and complete rating scales and questionnaires accurately
• Able to provide informed consent
• Potential participants must be able to identify at least one "locator" person to assist in tracking the participant for follow-up assessments

You may not qualify if…

• Other current substance dependence requiring immediate detoxification
• Diagnosis of schizophrenia, bipolar disorder, current major depressive disorder
• Currently suicidal or at high risk for suicide in the judgment of the investigator
• Carrying a medical device incompatible with MRI (e.g., metal implants such as surgical clips or pacemakers and extensive dental work such as bridges) or suffering from significant claustrophobia that would make MRI unfeasible.
• Size incompatible with MRI procedures
• Serious medical illness including HIV-1 infection
• Hepatitis C + titer with liver enzymes more than 2x normal or a Mini-Mental Status Exam Score of <25/30
• Insulin dependent diabetes mellitus (IDDM) or non- insulin dependent diabetes mellitus (NIDDM) and abnormal Hemoglobin A1C
• Severe hepatic or renal impairment
• History of seizure disorder, delirium, dementia, or mental disorders due to general medical conditions
• History of head trauma or stroke with lasting neurological sequelae
• Tardive dyskinesia, extrapyramidal movement disorder, Parkinson's Disease or history of Neuroleptic Malignant Syndrome
• Clinical or laboratory evidence of uncontrolled hypothyroidism/hyperthyroidism
• Orthostatic hypotension, defined as a decrease of at > 10 mm Hg in systolic blood pressure and/or an increase in heart rate of > 20 beats per minute, measured one minute following transition from a supine to a standing position.
• History of allergy or hypersensitivity to Risperidone
• Treatment with: Neuroleptics, Antidepressants, Antiarrhythmics, Carbamazepine, Phenytoin, Valproate, Rifampin, Phenobarbital, Levodopa and other dopamine agonists, Fluoxetine, Interferon, Propylthiouracil, Methimazole, Opiates.
• Treatment within 30 days prior to screening with an investigational drug or medication with the potential to influence cocaine use outcomes

Where it is running

• MGH Addiction Research Program — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.